PSMA-PET Uncovers Hidden Metastases and Reshapes Prostate Cancer Staging

A large multicenter study has delivered some of the clearest real-world evidence yet that conventional imaging systematically underestimates the spread of prostate cancer at the moment of diagnosis. In research published in the European Journal of Nuclear Medicine and Molecular Imaging, an international team led by Francesco Mattana and Francesco Ceci compared the performance of prostate-specific membrane antigen positron emission tomography, known as PSMA-PET, against the traditional staging combination of contrast-enhanced computed tomography and bone scintigraphy. Their conclusion is striking: the molecular imaging technique identified roughly twice as many men with oligometastatic disease, a limited form of spread that may still be treatable with curative intent, and it changed the intended treatment plan for more than a third of all patients studied.

The concept of oligometastatic disease sits at one of the most consequential fault lines in modern oncology. It describes an intermediate state in which cancer has spread beyond the primary organ but only to a small number of sites, conventionally defined in this study as three or fewer metastatic lesions. Unlike widespread metastatic disease, which is managed with systemic therapy aimed at control rather than cure, oligometastatic prostate cancer may be amenable to metastasis-directed therapies such as stereotactic body radiotherapy or surgery targeting individual lesions. Randomized trials including STOMP and ORIOLE have suggested that ablating these limited deposits can delay progression, and trials such as ARTO and RADIOSA have explored combining such approaches with hormonal therapy. But every one of these strategies depends on one thing: knowing exactly which patients truly have only a handful of metastases. That is where the accuracy of the staging scan becomes decisive.

PSMA-PET works on a fundamentally different principle from conventional imaging. Rather than relying on anatomical changes, such as an enlarged lymph node or a bone lesion visible on a scintigram, it uses a radioactive tracer that binds to prostate-specific membrane antigen, a molecule abundantly expressed on the surface of most prostate cancer cells. When injected intravenously, the labeled ligand accumulates in PSMA-expressing tissue, and the PET scanner maps this molecular signal across the whole body, typically fused with computed tomography for anatomical correlation. The result is a functional image that can reveal metastases only a few millimeters in size, long before they distort anatomy enough to be caught by CT or bone scan. Joint procedure guidelines from the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging, along with standardized reporting frameworks such as E-PSMA and PROMISE version 2, have progressively codified how these scans should be acquired and interpreted.

To test how this translates into everyday clinical practice, the researchers assembled a retrospective cohort of 497 patients with intermediate- to high-risk prostate cancer drawn from multiple centers. Of these, 255 men had undergone both PSMA-PET and conventional imaging within a four-month window, satisfying the strict inclusion criteria for the primary analysis. The primary endpoint was the detection rate of oligometastatic disease, defined as three or fewer metastatic sites, under each modality. The secondary endpoint examined whether the PSMA-PET findings altered the intended clinical management, as judged by a retrospective multidisciplinary review of each case.

The numbers tell a clear story. PSMA-PET identified oligometastatic disease in 11.4 percent of the analyzed patients, or 29 of 255 men, compared with just 6.7 percent, or 17 of 255, using conventional imaging, a difference that reached statistical significance with a p-value of 0.040. In other words, for every hundred men staged with conventional scans alone, roughly five who actually harbored limited metastatic disease would have been misclassified as having localized cancer. The molecular technique also detected more patients with multimetastatic disease, meaning widespread spread beyond the oligometastatic threshold. This pattern of reclassification, in which a more sensitive test shifts patients into more advanced disease categories, is what epidemiologists call stage migration, and it has profound implications for how clinical statistics and treatment decisions are framed.

Perhaps the most clinically resonant finding concerned treatment planning. When a multidisciplinary panel re-reviewed each case in light of the PSMA-PET results, the intended management changed in 36.5 percent of patients, or 93 of the 255 studied. These changes split roughly evenly into major and minor categories, each accounting for about 18 percent of the cohort. A major change typically meant a fundamental shift in therapeutic strategy, for example abandoning a planned curative treatment such as radical surgery or radiotherapy in favor of systemic therapy once previously invisible metastases came to light. Minor changes included adjustments within a general strategy, such as modifying the radiation field or adding hormonal therapy. The authors are careful to note that these figures reflect the intended treatment plan rather than the treatment actually delivered, an important distinction given the retrospective design.

The study’s authors are equally candid about its limitations, and understanding them is essential to interpreting the results correctly. Because the analysis was retrospective, there was no independent reference standard, such as histopathological confirmation of every detected lesion, against which the two imaging modalities could be judged. No central review of the images was performed, meaning scans were interpreted at the originating institutions under routine conditions. Crucially, no patient follow-up was available, so the study cannot say whether the additional detections by PSMA-PET translate into longer survival or better disease control. The authors explicitly state that their findings demonstrate increased detection and reclassification, not proven improvements in diagnostic accuracy or outcomes. This is a common and honest caveat in the stage migration literature: a more sensitive test will always find more disease, but only longitudinal data can confirm that finding it earlier and more completely helps patients live longer.

Even with those caveats, the results align with a growing body of prospective evidence. The landmark proPSMA trial, published in The Lancet in 2020, randomized men with high-risk prostate cancer to PSMA-PET or conventional imaging before curative-intent treatment and found superior accuracy for the molecular approach. Subsequent work has shown that PSMA-PET-guided staging is potentially cost-effective in European and American health systems, and diagnostic accuracy studies have confirmed high sensitivity for pelvic nodal metastases prior to radical prostatectomy. On the therapeutic side, the same PSMA target has been exploited for treatment, most notably with lutetium-177-PSMA-617 radioligand therapy, which improved survival in metastatic castration-resistant prostate cancer in a landmark New England Journal of Medicine trial. The imaging and therapeutic applications of PSMA thus form a theranostic pipeline in which the molecule that reveals the cancer also becomes the vehicle for destroying it.

Why does accurate identification of oligometastatic disease matter so much right now? Because the treatment landscape for advanced prostate cancer is fragmenting into increasingly tailored options. Men with de novo metastatic hormone-sensitive disease benefit from intensification strategies, including androgen deprivation therapy combined with docetaxel or androgen receptor pathway inhibitors such as abiraterone and darolutamide, as established by trials including CHAARTED, LATITUDE, PEACE-1 and ARASENS. Men with limited metastatic disease, by contrast, may be candidates for metastasis-directed therapy, potentially avoiding or deferring systemic side effects. The boundary between these populations is exactly where PSMA-PET is drawing a sharper line. If conventional imaging leaves oligometastatic patients hidden within the localized cohort, they may receive curative-intent local therapy that cannot address their occult spread. If it leaves them hidden within the multimetastatic cohort, they may receive systemic therapy forgoing potentially curative ablative treatment. Either misclassification carries a cost.

The practical consequence of this study is likely to be a strengthening of the case for PSMA-PET as the default staging modality for intermediate- and high-risk prostate cancer, a position already reflected in contemporary European Association of Urology guidelines. For patients, the message is that the type of staging scan they receive can genuinely determine which treatment pathway they are offered. For clinicians and trialists, the stage migration documented here means that historical survival statistics, which were built on conventional imaging cohorts, cannot be directly compared with outcomes in PSMA-PET-era populations, since the same label now describes patients with different underlying disease burdens. Future prospective studies with long-term follow-up will need to establish whether reclassifying these men improves survival. What this real-world analysis establishes today is simpler but consequential: the scans that medicine relied on for decades were missing metastatic disease in a meaningful fraction of men, and a molecular imaging technique that sees what those scans cannot is already changing the plan of care for more than one in three patients.

Subject of Research: The role of PSMA-PET in detecting oligometastatic prostate cancer and driving stage migration compared with conventional imaging

Article Title: Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease

Article References: Mattana, F., Luzzago, S., Dragonetti, V., Kasivisvanathan, V., Conlon, S., Castellucci, P., Farolfi, A., Miszczyk, M., Techmański, T., Rajwa, P., Shariat, S. F., Zattoni, F., Reitano, G., Briganti, A., Montorsi, F., Frassoni, S., Bagnardi, V., Gandaglia, G., & Ceci, F. (2026). Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08166-w

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08166-w

Keywords: prostate cancer, PSMA-PET, oligometastatic disease, stage migration, nuclear medicine, cancer staging, metastasis-directed therapy, conventional imaging, molecular imaging, stereotactic body radiotherapy, theranostics, clinical staging